NCT04414813

Stereotactic Transplantation of hAESCs for Parkinson's Disease

Clinical Study of Stereotactic Transplantation of Human Amniotic Epithelial Stem Cells (hAESCs) in the Treatment of Parkinson's Disease (PD)

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Shanghai East Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of stereotactic transplantation of hAESCs for Parkinson's disease.

Detailed description

The study plans to recruit 3 participants with Parkinson's disease . Using stereotactic technology, hAESCs will be accurately transplanted into the lateral ventricle. Therapeutic effectiveness and safety of hAESCs on PD will be evaluated. hAESCs are derived from placental amnion donated after cesarean section in healthy women. hAESCs is developed from the epiblast as early as 8 days after fertilization, recent reports indicate that hAESCs have some characteristics of neural stem cell. These cells are able to differentiate into dopaminergic neurons and secrete dopamine and various neurotrophic factors. These HAESCs could be seen as one of the best potential stem cell source for treating Parkinson's disease.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
BIOLOGICAL	Human Amniotic Epithelial Stem Cells	Stereotactic transplantation of hAESCs for participants with PD.

Timeline

• Start date: 2020-10-08
• Primary completion: 2023-02-08
• Completion: 2023-02-08
• First posted: 2020-06-04
• Last updated: 2023-04-12

Locations

1 site across 1 country: China